久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Latest

China approves patent to COVID-19 vaccine

By Zhang Zhihao | chinadaily.com.cn | Updated: 2020-08-16 19:15
Share
Share - WeChat
A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken on April 10, 2020. [Photo/Agencies]

China has granted its first COVID-19 vaccine patent to the adenovirus vector vaccine developed by Chen Wei of the Academy of Military Medical Sciences and Chinese biotech company CanSino Biologics, according to the National Intellectual Property Administration.

The patent was submitted for application on March 18, and was approved on Aug 11, according to the patent document.

The vaccine, dubbed "Ad5-nCoV", uses a weakened common cold virus to introduce genetic material from the novel coronavirus into the human body. The goal is to train the body to produce antibodies that recognize the coronavirus’s spike protein and fight it off.

The phase-two clinical trial of the vaccine has found it is safe and can induce an immune response, according to research published in the journal Lancet last month. The phase-three clinical trial, which will include more participants and be conducted overseas, is currently in the pipeline.

Experts have called adenovirus vector vaccine a promising technique for its safety and potency against COVID-19 based on current evidence, as well as its potential in mass production. The United Kingdom and Russia are also working on a vaccine candidate using this kind of technology.

However, many pressing questions regarding the vaccine candidate remain, such as the longevity of the protection, the appropriate dosage to trigger a strong immune response, and whether there are host-specific differences. These questions will be probed in the larger scale phase-three trials.

Another caveat is that with the vector for the vaccine being a common cold virus, people may have preexisting immunity that kills the viral carrier before the vaccine can take effect, which could partially hamper the immune responses.

Compared with younger people, older participants generally had significantly lower immune responses, the Lancet study found. As a result, elderly people might require an additional dose to induce a stronger immune response, but further research would be needed to evaluate this approach.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 亚洲免费网 | 亚洲精品国自产拍影院 | 亚洲经典在线 | 中文字幕 亚洲精品 第1页 | 欧美一级手机免费观看片 | 丁香伊人五月综合激激激 | 91九色精品国产免费 | 亚洲 欧美 手机 在线观看 | 国产精品欧美一区二区三区不卡 | 亚洲免费网站观看视频 | 美女色黄网站 | 久久久久欧美精品 | 国产大学生自拍 | 亚洲一区二区免费 | 广东毛片 | 免费日本在线视频 | 又黄又www| 久久精品亚洲乱码伦伦中文 | 自拍偷拍亚洲区 | 狠狠色婷婷丁香综合久久韩国 | 99久久国内精品成人免费 | 国产成人精品女人不卡在线 | 特级毛片aaa免费版 特级毛片a级毛免费播放 | 成年人在线看片 | 日韩三级免费观看 | 成人免费视频软件网站 | 看一级毛片 | 精品久久久久久国产 | 欧美一级毛片aaa片 欧美一级毛片不卡免费观看 | 毛片免费全部播放一级 | 国产亚洲午夜精品a一区二区 | 91视频啪啪 | 日韩欧美一二区 | 400部大量精品情侣网站 | 欧美视频在线观看免费精品欧美视频 | 国产精品正在播放 | 国内精自线一二区 | 国产高清视频在线播放 | 亚洲欧洲日产v特级毛片 | 免费一级视频在线播放 | 好湿好紧好痛a级是免费视频 |